- Physicians practicing in opioid agonist treatment (OAT) clinics recognize the importance of HCV testing and treatment for people who inject drugs (PWID), but report poor self-perceived competency for infection management and treatment.
Why this matters
- Findings highlight a need for improved HCV education and training among drug treatment providers.
- 2017 C-SCOPE online survey involving 203 eligible physicians from OAT clinics in Europe (45%), the United States (40%), Canada (8%), and Australia (6%).
- Competence self-assessed on a 7-point scale (4=average).
- Funding: MSD.
- Common specialties: psychiatry (29%), addiction medicine and psychiatry (21%, 20%), and general practice/family physician (19%).
- Mean years in practice, 11; mean PWID managed, 51 (with HCV, 24).
- Most perceived HCV testing (86%) and treatment (82%) as important.
- Few reported below-average competency for regular screening (12%) and interpretation (14%).
- Below-average competency was more commonly reported for:
- Advising patients on new HCV therapies (27%).
- Knowledge of new options (36%).
- HCV treatment/management (40%).
- In adjusted analysis, factors predictive of average-or-less competency for HCV treatment/management included: fewer years in practice, fewer HCV patients over the last 6 months, not having obtained relevant information, no training in the last year, and not having read or consulted HCV guidelines.
- Potential selection bias.